80,000 shares at a cost of $10,193 represents a 12.7 cents per share average cost price.
Showing 25 of 264
The company expects to supply medicinal cannabis to patients from around March 2019.
The company has finalised negotiations with California-based company VaporSpec.
The company has purchased the property for $2.6 million in the Northern Rivers district of NSW.
Quentin Megson will serve jointly in the role with existing company secretary Susan Hunter.
The Root Zone Temperature Optimisation (RZTO) technology stabilises plant root zone temperatures, optimising plant physiology.
The halt will remain in place until the start of trading on Friday or when an announcement is released.
The new name reflects strategic developments in the company’s global medicinal cannabis business.
Non-executive director Max Johnston now holds 200,000 shares in an indirect interest.
CannaHub is a new addition to the MGC projects currently underway with the Royal Melbourne Institute of Technology, and will be formally launched in Q1 2019.
The company is working to raise awareness of its products among mainstream doctors and aims to reach 1,000 patients by this time next year.
The low-cost heating and cooling system warms roots during winter and cools them in summer.
The halt will remain until the start of trading on November 5 or when an announcement is released.
The Sydney-based investor has demonstrated confidence in the company’s medical research strategy.
The company is well-positioned to benefit from the ongoing sale of its cannabis oils to patients through approved prescribers.
The life science company is developing products for the e-cigarette liquid market as well as for the food additive and supplement markets.
The company listed on the ASX last month and its shares increased 180% on its first trading day.
The company has a vertically integrated model incorporating a growing site, an R&D facility and a manufacturing facility.
The company has this week entered into a cannabis concentrate program agreement with a Canadian company.
The company has started manufacturing the product and plans to launch it later this year.
TSX Venture Exchange-listed MediPharm Labs Inc will have its medicinal and recreational products distributed by a large-scale licensed producer.
Non-executive director Max Johnston has acquired shares on-market valued at more than $9,000.
The company is increasing the capacity of its hemp-derived cannabidiol production facility in the US.
Three studies are the focus as the company targets chronic illnesses, including cancer, using a pipeline that includes cannabis products and probiotics.
Professor David Casarett and Dr Dustin Sulak add clinical expertise and depth to the board.